Switch theme
Sign up to access all valuation multiples
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
1997
250
LTM Revenue $109M
LTM EBITDA -$179M
$364M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xencor has a last 12-month revenue of $109M and a last 12-month EBITDA of -$179M.
In the most recent fiscal year, Xencor achieved revenue of $110M and an EBITDA of -$186M.
Xencor expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xencor valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $168M | $110M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$127M | -$186M | XXX | XXX | XXX |
| EBITDA Margin | -76% | -168% | XXX | XXX | XXX |
| Net Profit | -$55.2M | -$126M | XXX | XXX | XXX |
| Net Margin | -33% | -114% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Xencor's stock price is $9.
Xencor has current market cap of $630M, and EV of $364M.
See Xencor trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $364M | $630M | XXX | XXX | XXX | XXX | $-3.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Xencor has market cap of $630M and EV of $364M.
Xencor's trades at 3.3x LTM EV/Revenue multiple, and -2.0x LTM EBITDA.
Analysts estimate Xencor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Xencor and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $364M | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.0x | XXX | XXX | XXX |
| P/E | -2.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpXencor's NTM/LTM revenue growth is 8%
Xencor's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Xencor's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Xencor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Xencor and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -34% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -168% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -160% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 55% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 206% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 261% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xencor acquired XXX companies to date.
Last acquisition by Xencor was XXXXXXXX, XXXXX XXXXX XXXXXX . Xencor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Xencor founded? | Xencor was founded in 1997. |
| Where is Xencor headquartered? | Xencor is headquartered in United States of America. |
| How many employees does Xencor have? | As of today, Xencor has 250 employees. |
| Who is the CEO of Xencor? | Xencor's CEO is Dr. Bassil I. Dahiyat, PhD.. |
| Is Xencor publicy listed? | Yes, Xencor is a public company listed on NAS. |
| What is the stock symbol of Xencor? | Xencor trades under XNCR ticker. |
| When did Xencor go public? | Xencor went public in 2013. |
| Who are competitors of Xencor? | Similar companies to Xencor include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Xencor? | Xencor's current market cap is $630M |
| What is the current revenue of Xencor? | Xencor's last 12-month revenue is $109M. |
| What is the current EBITDA of Xencor? | Xencor's last 12-month EBITDA is -$179M. |
| What is the current EV/Revenue multiple of Xencor? | Current revenue multiple of Xencor is 3.3x. |
| What is the current EV/EBITDA multiple of Xencor? | Current EBITDA multiple of Xencor is -2.0x. |
| What is the current revenue growth of Xencor? | Xencor revenue growth between 2023 and 2024 was -34%. |
| Is Xencor profitable? | Yes, Xencor is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
